Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy

被引：0
|
作者：
Mohyuddin, Ghulam Rehman [1 ]
Chakraborty, Rajshekhar [2 ]
Calip, Gregory S. [3 ]
Ascha, Mustafa S. [3 ]
Wang, Xiaoliang [3 ]
Rubinstein, Samuel M. [4 ]
Tuchman, Sascha [4 ]
Costa, Luciano [5 ]
Haaland, Benjamin [6 ]
Giri, Smith [5 ]
Mian, Hira [7 ]
Fonseca, Rafael [8 ]
Sborov, Douglas [1 ]
机构：
[1] Univ Utah, Huntsman Canc Inst, Div Hematol & Hematol Malignancies, Salt Lake City, UT 84112 USA
[2] Columbia Univ, Dept Hematol, New York, NY USA
[3] Flatiron Hlth, New York, NY USA
[4] Univ North Carolina Chapel Hill, Lineberger Comprehens Canc Ctr, Dept Med, Div Hematol, Chapel Hill, NC USA
[5] Univ Alabama Birmingham, Div Hematol & Oncol, Birmingham, AL USA
[6] Univ Utah, Dept Populat Sci, Salt Lake City, UT USA
[7] McMaster Univ, Dept Oncol, Hamilton, ON, Canada
[8] Mayo Clin Arizona, Div Hematol & Oncol, Phoenix, AZ USA
来源：
BLOOD CANCER JOURNAL | 2022年 / 12卷 / 12期
关键词：
D O I：
10.1038/s41408-022-00769-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy
    Mohyuddin, Ghulam Rehman
    Chakraborty, Rajshekhar
    Calip, Gregory
    Ascha, Mustafa S.
    Wang, Xiaoliang
    Rubinstein, Samuel
    Tuchman, Sascha A.
    Costa, Luciano J.
    Haaland, Benjamin
    Giri, Smith
    Mian, Hira S.
    Fonseca, Rafael
    Sborov, Douglas W.
    BLOOD, 2022, 140 : 5223 - 5224
  • [2] Prognostic value of translocation 11;14 in patients with relapsed/refractory myeloma receiving anti-CD38 therapy
    Ghulam Rehman Mohyuddin
    Rajshekhar Chakraborty
    Gregory S. Calip
    Mustafa S. Ascha
    Xiaoliang Wang
    Samuel M. Rubinstein
    Sascha Tuchman
    Luciano Costa
    Benjamin Haaland
    Smith Giri
    Hira Mian
    Rafael Fonseca
    Douglas Sborov
    Blood Cancer Journal, 12
  • [3] Determinants of Response to Anti-CD38 and Bispecific Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma
    Aleman, Adolfo
    Zajdman, Ariel Kogan
    Mouhieddine, Tarek
    Upadhyaya, Bhaskar
    Van Oekelen, Oliver
    Lagana, Alessandro
    Grossman, Leah
    Thibaud, Santiago
    Sanchez, Larysa
    Richard, Shambavi
    Rossi, Adriana
    Richter, Joshua
    Cho, Hearn Jay
    Rodriguez-Valdes, Cesar
    Chari, Ajai
    Parekh, Samir
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S41 - S41
  • [4] Prognostic Value of FDG-PET/CT Parameters in Patients with Relapse/Refractory Multiple Myeloma before Anti-CD38 Based Therapy
    Fouquet, Guillemette
    Wartski, Myriam
    Dechmi, Amina
    Willems, Lise
    Deau-Fischer, Benedicte
    Franchi, Patricia
    Descroocq, Justine
    Deschamps, Paul
    Blanc-Autran, Estelle
    Clerc, Jerome
    Bouscary, Didier
    Barreau, Sylvain
    Chapuis, Nicolas
    Vignon, Marguerite
    Cottereau, Anne-Segolene
    CANCERS, 2021, 13 (17)
  • [5] Pharmacy considerations: Use of anti-CD38 monoclonal antibodies in relapsed and/or refractory multiple myeloma
    Shah, Bhavesh
    Gray, Joy
    Abraham, Ivo
    Chang, Melody
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 170 - 182
  • [6] Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
    Xavier Leleu
    Thomas Martin
    Katja Weisel
    Fredrik Schjesvold
    Shinsuke Iida
    Fabio Malavasi
    Salomon Manier
    Enrique M. Chang-Ki Min
    Charlotte Ocio
    Aurore Pawlyn
    Hang Perrot
    Joshua Quach
    Ivan Richter
    Kwee Spicka
    Paul G. Yong
    Annals of Hematology, 2022, 101 : 2123 - 2137
  • [7] Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
    Leleu, Xavier
    Martin, Thomas
    Weisel, Katja
    Schjesvold, Fredrik
    Iida, Shinsuke
    Malavasi, Fabio
    Manier, Salomon
    Min, Chang-Ki
    Ocio, Enrique M.
    Pawlyn, Charlotte
    Perrot, Aurore
    Quach, Hang
    Richter, Joshua
    Spicka, Ivan
    Yong, Kwee
    Richardson, Paul G.
    ANNALS OF HEMATOLOGY, 2022, 101 (10) : 2123 - 2137
  • [8] The Anti-CD38 Antibody Therapy in Multiple Myeloma
    Petrucci, Maria Teresa
    Vozella, Federico
    CELLS, 2019, 8 (12)
  • [9] A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma
    Zhang, Huan
    Liu, Man
    Xiao, Xia
    Lv, Hairong
    Jiang, Yanyu
    Li, Xin
    Yuan, Ting
    Zhao, Mingfeng
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1418 - 1427
  • [10] Efficacy and safety of anti-CD38 antibodies in combination with pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma
    Sato, Tsuyoshi
    Asano, Kazuya
    Maeta, Takahiro
    Kiyohara, Kazuki
    Miyajima, Shinri
    Otsu, Akihiro
    Nishiya, Maki
    Sasaki, Ryousei
    Okano, Yoshiaki
    Kamihara, Satsuki
    Kowata, Shugo
    Oyake, Tatsuo
    Ito, Shigeki
    ANNALS OF ONCOLOGY, 2023, 34 : S1446 - S1446
12345